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As the discussion continues around how best to provide HIV-prevention products and services to women, deepening 
the understanding of the service-delivery context and health-seeking behaviors of women provides a useful 
foundation upon which to build effective education and service-delivery efforts. The Population Council, in 
partnership with Solutions IPPT, conducted this study to learn more about women’s experiences in routine primary 
health care (PHC) centers in Mpumalanga, South Africa, to inform microbicides introduction.   
Based on the results of the CAPRISA 004 trial conducted in South Africa, which showed that use of 1 percent 
tenofovir gel, an antiretroviral (ARV)-based microbicide, resulted in a 39 percent reduction in risk of HIV infection 
among women (Abdool Karim et al. 2010), the international community began to prepare for the introduction of 
tenofovir into health systems. This study was conducted while FACTS 001, a trial designed to confirm the results of 
CAPRISA 004, was underway. Although the focus was on tenofovir vaginal gel as the potential product, the study 
sought to identify and highlight key programmatic, socio-behavioral, and user-related issues that are relevant to any 
ARV-based prevention product.   
The provision of any new prevention product in clinical trial settings is often vastly different from implementation in 
“real life” public sector settings. In addition, use of ARVs, such as tenofovir gel, for pre-exposure prophylaxis (PrEP) 
will require regular HIV testing to ensure users are uninfected before initiating and continuing product use. 
Therefore, before any ARV-based prevention product can be introduced to women, information is needed on HIV 
testing practices, how best to integrate products into existing primary health care systems, including within sexual 
and reproductive health (SRH) and HIV-prevention services, and women’s risk perception and health-seeking 
behaviors. This study explores these issues.   
Key insights from this study discussed in detail in this report are as follows:  
• Service seeking—Among the population of women attending PHC centers, the most commonly sought services of 
study participants were: well-baby (30 percent), family planning (FP) (17 percent), antenatal care (10 percent), 
and HIV testing and counseling (10 percent). These services may afford good opportunities to integrate new HIV-
prevention products as they become available. 
• Constellation of services—The potential range of HIV-related services (prevention and treatment, care, and 
support) at PHC centers is impressive. There is variability in how these services are implemented; the 
comprehensiveness of services is uneven across study sites. 
• HIV testing behavior—The vast majority of women (93 percent) reported having been tested for HIV at least once in 
their life. Among women who came for FP or well-baby services, 69 percent had been tested more than once in 
the previous year. Importantly, program managers and providers confirmed that women had been coming for 
testing. 
• Self-assessment of risk—About one-fifth of women appeared to have a fairly accurate risk self-assessment based 
on a composite measure of risk (CMR) created from response to a battery of key questions. More than half either 
underestimated or did not know their risk based on the same CMR.   
• Interest in tenofovir gel—While most women had not heard of tenofovir gel before this study, the majority reported 
“willingness to try” it if it were available. One-half of study participants said they would be willing to come for 





Despite recent declines in HIV incidence overall, the number of new infections among women remains high 
(UNAIDS 2014). The UNAIDS “Global Plan Towards the Elimination of New HIV Infections Among Children by 
2015 and Keeping Their Mothers Alive” targeted a 50 percent reduction in HIV incidence among women of 
reproductive age (15–49 years old) between 2009 and 2015. By the end of 2013, however, incidence had 
only declined by 17 percent. Additional HIV-prevention strategies, including both biomedical and behavioral 
interventions, are clearly needed to achieve this goal.  
Behavioral interventions, such as condom use and reduction of sexual partners, have contributed to the 
reduction in heterosexual transmission, yet many people are still at high risk (Steen et al. 2009). Biomedical 
interventions, such as voluntary medical male circumcision (VMMC) and use of antiretrovirals (ARV) for 
prevention, are now being introduced (PEPFAR 2011). Post-exposure prophylaxis (PEP) is available in several 
countries (AIDSTAR-One 2012), and the use of ARVs prior to exposure (PrEP) has been found effective in a 
number of settings (Grant et al. 2010; Baeten et al. 2012; Thigpen et al. 2012).  
South Africa continues to be one of the countries hardest hit by HIV and AIDS, despite recent gains in 
treatment and prevention. According to UNAIDS, overall HIV prevalence in the general population is estimated 
at 17.9 percent (UNAIDS 2013). Of the 6.1 million people living with HIV, more than half are females 15 and 




Context and Rationale 
In 2010, the CAPRISA 004 trial conducted in South Africa showed that use of 1 percent tenofovir gel, an ARV-
based microbicide, resulted in a 39 percent reduction in risk of HIV infection among women (Abdool Karim et 
al. 2010). Based on these promising findings, the international community began preparing for the 
introduction of tenofovir gel (USAID 2011). However, the provision of a microbicide in clinical trial settings is 
vastly different from implementation in “real life” public sector settings, and important questions must be 
addressed, such as who to target for tenofovir gel, how it will be provided, and by whom. Before tenofovir gel or 
other ARV-based prevention products can be introduced to women, information is needed on HIV testing 
practices, how best to integrate products into existing primary health care (PHC) systems, including within 








The overall goal of this study was to pave the way for the introduction of tenofovir gel or other ARV-based 
prevention products for women by exploring the populations to target, the types of services through which 
tenofovir gel might be provided, by whom, and under what service-delivery conditions. 
Specifically, the study objectives were to: 
• Document the socio-demographics, HIV-risk perception, HIV testing behaviors, nature and frequency of potential 
HIV exposure, and use of HIV-prevention and SRH services among female clients at routine PHC services.  
• Document clients’ perspectives on ARV-based prevention and tenofovir gel specifically, including their interest and 
willingness to try such products in the future. 
• Gather insights from a select number of facility and program managers about the potential role that tenofovir gel 
could play in their programs and the challenges and opportunities around its introduction. 
STUDY DESIGN 
A descriptive, cross-sectional study was carried out in five high-volume PHC facilities1  offering a range of HIV and/or 
SRH services in Mpumalanga, South Africa. Data were collected during a six-week period among clients through 
structured, quantitative, interviewer-administered face-to-face exit interviews and paper-based self-administered 
anonymous questionnaires. In addition, semi-structured interviews (SSIs) were conducted with a small number of 
provincial health program managers and service providers. 
STUDY SETTING 
Despite being the second smallest province in South Africa, Mpumalanga (76,495 km2; population 4,039,939 
[Census 2011]), has the second highest HIV prevalence (35.1 percent) in the country (National Department of 
Health 2010). Figure 1 provides an illustration of the province with district and subdistrict demarcations. 
 
                                                                        
 
1Family planning (FP), reproductive health (RH), and HIV counseling and testing (HCT) are provided within the 




FIGURE 1. HIV PREVALENCE ESTIMATES FOR MPUMALANGA, SOUTH AFRICA 
 
 








Nkangala District – 32.6% HIV Prevalence
Gert Siband District – 38.2% HIV Prevalence






High-volume facilities meeting the following criteria were selected: provide HIV testing services, HIV-prevention 
services, FP services, client load of >200 per month, and have more than two professional nurses on staff. A list of 
all facilities meeting these criteria was obtained from the provincial Department of Health (DoH) in Mpumalanga. At 
least four sites were required to enable the use of parametric measures for data analysis (Hayes and Moulton 
2009). A target sample of six sites was randomly selected to achieve reasonable balance with regard to total client 
load, staff available, rural and urban location, and subdistrict. A statistician used a basic two-stage sampling 
procedure to randomly select sites for each district. After the clinics were selected, the Solutions IPPT team 
(Pretoria, South Africa) confirmed the choices in consultation with the district leadership, and after inspecting each 
site to ensure that it met the study criteria. Prior to study start, one of the selected clinics burned down; therefore, 
the study was implemented at five clinics. 
RESPONDENT SELECTION 
A convenience sample of women aged 18 or older accessing any type of health services (e.g., HIV counseling and 
testing [HCT], FP, antenatal care, well-baby) at any of the five PHC facilities during the six-week data-collection period 
were invited to participate in the study. Each day, fieldworkers approached all women who appeared to be 18 years 
of age or older who presented for any type of service. Clients were told about the study while they were waiting for 
the service(s) they had come for, and were asked if they were interested in participating. Those who agreed were 
asked to sign an informed consent form. Then, at the end of their clinic visit, women met with a fieldworker who 
conducted a standardized, face-to-face, structured exit interview. Women who took part in an exit interview were 
also asked if they would be willing to complete an anonymous self-administered questionnaire. Those who agreed 
completed the paper questionnaire, sealed it in the envelope provided, and placed it in a box on the way out of the 
facility. 
Solutions IPPT staff invited the managers of each of the five study clinics as well as program managers at the district 
and provincial levels to participate in semistructured interviews (SSIs) conducted either in-person or by telephone .  
DATA COLLECTION  
A team of two fieldworkers was assigned to each facility, sharing the workload of recruiting and interviewing clients. 
Exit interviews contained questions about health-seeking behaviors, HIV testing practices, FP use, and reasons for 
attending the clinic on the day of the interview. On completion of the face-to-face exit interviews, women were asked 
to complete a self-administered anonymous questionnaire. This questionnaire captured sensitive information 
regarding sexual behavior that may be difficult to answer in a face-to-face interview format. Both questionnaires (exit 
interview and anonymous self-interview) were translated and, after pilot testing, back translated into the relevant 
local languages: Ndebele, Sepedi, Siswati, Tsonga, and Zulu. Clients were asked to choose their preferred interview 
language from the five local languages, or English. The SSIs, which were conducted by Solutions IPPT staff members 
using a standardized moderator’s guide, were audio-recorded and transcribed by the Solutions IPPT team. 
Data collection and management was coordinated by Solutions IPPT with oversight from the Population Council 
(Johannesburg, South Africa, and New York, NY, USA). A fieldworker-training workshop was held and included: (1) 
review of concepts of SRH and ARV-based HIV prevention, with an emphasis on tenofovir gel; (2) quantitative 
interviewing skills; (3) key considerations in conducting research on SRH and sexual practices; and (4) a thorough 
review of the instruments, including practice with mock interviews. The training highlighted the importance of 
confidentiality and informed consent in research. During the training, all fieldworkers completed an NIH research 
ethics course and certification test. Once data collection began, field supervisors based at Solutions IPPT traveled 






Quantitative data from exit interviews and self-administered questionnaires were entered in Epi Info by the Solutions 
IPPT data manager. Field supervisors oversaw data entry, management, and data cleaning during the study. Data 
were exported from Epi Info into SAS (Version 9.4) for analysis. Responses to all questions from the exit interviews 
and the anonymous questionnaires were summarized, with frequency distributions for categorical responses, and 
mean, standard deviation, and range for numeric responses. Some numeric responses (such as age) were also 
grouped into categories for summarization. Numeric and categorical summaries were calculated for socio-
demographic data within and across sites. Proportions were calculated for the percentage of clients who had been 
previously tested for HIV, who had heard of vaginal microbicides, and who reported that they would be interested in 
using a microbicide in the future. Chi-square tests were used to assess the associations between the service(s) 
women came for (per the exit interview) and their self-assessed level of HIV risk (per the anonymous questionnaire). 
Chi-square tests were also performed to identify significant differences between age groups for: ever tested for HIV, 
tested for HIV in the last year, and tested for HIV more than once in the last year.  
Qualitative data from the SSIs with facility and program managers were analyzed thematically by the New York–
based study team.  
ETHICAL CONSIDERATIONS 
The study protocol was reviewed and approved by the Institutional Review Boards of the Population Council and the 
University of Witwatersrand in Johannesburg, South Africa, and by the Mpumalanga DoH. The informed consent 
process included a description of the study, procedures to be followed, possible discomforts and risks, benefits, 
compensation, and confidentiality. Women were informed that they would not benefit directly from participating in 
the study and that no monetary compensation would be provided. Women were also told that they had the right to 
withdraw from the study at any time or refuse to answer any questions that were uncomfortable for them. Clinic staff 
assisted in facilitating space for interviews, either in private rooms within the clinics, outdoors under trees, or in 
other private spaces. None of the data collected included personal identifiers. Study participants and records could 







The study team aimed to interview 1,200 women in the specified data-collection period, which, due to 
budgetary and logistical constraints, was set at six weeks. During this data- collection period a total of 2,432 
women were approached at the clinic sites and told about the study. Of those, 1,227 women (50 percent) 
enrolled and completed an exit interview and 991 of those women (80 percent) also completed a self-
administered anonymous questionnaire. It is noteworthy that interviews were conducted with women after 
they received services, which meant that their overall time spent at the clinic increased.  
This report highlights select themes by study objectives. As shown in Table 1, the study population was fairly 
equally distributed at four of the five sites; the fifth site, Boulders clinic had fewer participants (n=165; 13 
percent). Detailed information on the clinics can be found in the Appendix. The report highlights selected 
themes based on the study objectives. 
OBJECTIVE 1  
Document the sociodemographics, HIV risk perception, HIV testing behaviors, nature and frequency of 
potential HIV exposure, and use of HIV prevention and SRH services among female clients at routine PHC 
services.  
The majority (85 percent) of participants were between 20 and 49 years of age (range 18–70); the average 
age was 29. Most participants (79 percent) identified themselves as being single but in a steady 
relationship; 11 percent reported being married; 5 percent were single and not in a steady relationship; and 
a small number reported being divorced or widowed. Most participants (88 percent) had completed at least 






TABLE 1  Demographic profile of study participants 
 





N Percent N Percent 
Total 1,227 100 986 100 
Facility          
Allamansdrift B  246 20.1 244 24.75 
Boulders  165 13.5 60 6.09 
Fernie 1  255 20.8 241 24.44 
Marite  252 20.5 172 17.44 
Piet Retief  309 25.2 269 27.28 
Age group         
18-19  132 10.8 119 12.07 
20-24  349 28.4 302 30.63 
25-29  296 24.1 238 24.14 
30-34 190 15.5 151 15.31 
35-39 93 7.6 74 7.51 
40-44 71 5.8 53 5.38 
45-49 43 3.5 30 3.04 
50-70  51 4.2 17 1.72 
N/A 2 0.2 2 0.2 
Age: mean (range) 28.9 (18–70) 27.7 (18–63) 
Current relationship status          
Single (not in a relationship)  64 5.2 50 5.07 
Single (in a relationship)  967 78.9 790 80.12 
Married  137 11.2 104 10.55 
In a polygamous marriage  5 0.4 3 0.3 
Divorced  4 0.3 3 0.3 
Separated  8 0.7 5 0.51 
Widowed  20 1.6 11 1.12 
Other  21 1.7 20 2.03 
N/A 1 0.1 0 0 
Highest level of education completed     
 
  
Primary  131 10.7 54 5.48 
Secondary  988 80.6 851 86.31 
College certificate/diploma  70 5.7 62 6.29 
University degree  20 1.6 18 1.83 
Other  17 1.4 1 0.1 
N/A 1 0.1 0 0 





For success in introducing a new HIV-prevention technology, it is important to understand the types of services and 
outlets that would be most suitable for distributing the particular product. For an ARV-based prevention method for 
women, such as tenofovir gel, knowing the types of health services women seek, where they go for services, how 
they would like to receive information and counseling, and what their experiences have been interacting with the 
health system and health providers are all important factors to consider in determining how to best position a new 
product. 
When women completed the exit interview they were asked to identify which service or services they had come for 
that day. The two most commonly sought services were well-baby (31 percent) and FP (17 percent), and some 
women (16.2 percent) reported coming for more than one service (see Table 2).  
 
TABLE 2  Distribution of PHC clients according to type of service sought, by age  
Age group HIV testing & counseling Antenatal care Family planning 
Well-baby 
services Other service 
18–19  12 (1.0)   19 (1.6) 32 (2.6) 43 (3.5) 31 (2.5) 
20–24  31 (2.5)   46 (3.8) 68 (5.5)  123 (10.0) 105 (8.5) 
25–29  31 (2.5)   34 (2.8) 56 (4.6) 108 (8.8)  90 (7.3) 
30–34  22 (1.8)   13 (1.1) 36 (2.9)   53 (4.3)  77 (6.2) 
35–39    6 (0.5)     6 (0.5) 11 (0.9)   22 (1.8)  57 (4.6) 
40–44    6 (0.5)      3 (0.2)   5 (0.4)   17 (1.4)  47 (3.8) 
45–49    6 (0.5)      0 (0.0)   3 (0.2)     7 (0.6)  34 (2.8) 
50–70    6 (0.5)      0 (0.0)   0 (0.0)       2 (<0.1)    0 (0.0) 
Total 120 (9.8) 121 (10) 211 (17.1)    375 (30.5)  441 (35.7) 
NOTE: Other services included: ARV treatment (7.4%); care for chronic disease (6.4%); pregnancy testing (3.4%); TB treatment 
(2.4%); physical injury treatment (2.1%); PEP, emergency contraception, STI treatment, termination of pregnancy (<1% each); and 
“other” (15.7%). Two women did not indicate their age. 
  
 
HIV testing practices 
Use of ARVs such as tenofovir gel for PrEP will require regular HIV testing to ensure users are uninfected before 
initiating and continuing product use. Thus, understanding HIV testing practices among potential users is critical in 
planning for introduction. More than 90 percent of the women in the study knew their HIV status and 79 percent had 
disclosed this information to someone. Of the 1,227 participants who completed the exit interviews, 93 percent 
reported having been tested for HIV at least once, with significant differences by age group; whereas 94 percent of 
women aged 25–49 had ever been tested, 83 percent of 18–19 year olds and 82 percent of women 50 and older 
had ever been tested (chi-square p value < 0.001). Similarly, there were significant differences in the percentage of 
18–44 year olds (70 percent) versus women 45 and older (56 percent) who were tested within the last year 
(p=0.001). Figure 2 shows HIV testing practices according to age group.  
Chi-square tests also illustrated significant differences in HIV testing frequency by type of service sought. Among 
women who came for FP, 69 percent had been tested for HIV more than once in the previous year compared with 59 
percent of women who had not come for FP services (p=0.04). Similarly, 69 percent of women seeking well-baby 
services had been tested more than once in the previous year compared with 56 percent who had not come for well-
baby services (p=0.003). On the other hand, 42 percent of women who came for ANC had been tested for HIV more 
than once in the previous year compared with 63 percent of those who did not come for ANC. Finally, 62 percent of 
women who had ever been pregnant had been tested more than once in the last year compared with 49 percent of 





TABLE 3  Reasons women thinking they are not at risk of HIV 
Why do you think you are not at risk of  
getting HIV?*  N = 614 Percent 
I am not currently sexually active   59   9.8 
I have only one partner 240 39.7 
I have only ever had one partner   51   8.4 
I am married   23   3.8 
I use condoms every time I have sex 122 20.2 
I trust my partner   37   6.1 
My partner shared his status   39   6.4 
I get tested for HIV regularly   82 13.6 
Other reasons for not being at risk of HIV      3   0.5 
Refuse to answer reason for not being at risk   38   6.3 
*Denominator includes women who responded to any of the subsequent 
reasons for not being at risk.   
**N’s do not add up to 100% because multiple responses were possible. 
 
FIGURE 2  HIV TESTING PRACTICES REPORTED BY PHC CLIENTS ON EXIT INTERVIEWS, 




Risk perception  
Of critical importance to the introduction of HIV-prevention products is a more nuanced understanding of women’s 
perception of the risk and actions they are willing and able to take to protect themselves. Several models of health 
behavior, including the Health Belief Model (Glanz et al. 2002) and the Transtheoretical Model (Brown et al. 1991) 
include the construct of “risk” as a key element necessary for individual behavior change. Although women’s self-
assessment of their individual risk of getting HIV may or may not align with their actual risk, gaining a more nuanced 
understanding of how women characterize their level of risk (low to high) can help to inform prevention efforts.  
Women completing the anonymous 
questionnaire who reported being HIV-
negative (n=766) were asked to assess their 
level of HIV risk (none, low, medium, high, or 
unknown) and to indicate reasons they 
believed themselves to be at risk or not. 
Women’s self-assessed risk fell into 
approximately three categories: those who 
believed themselves to be at no to low risk 
(36.4 percent); those who thought they were 
at medium to high risk (27.4 percent); and 
those who did not know their risk (26.9 
percent). 
As shown in Table 3, having only one partner 
was the most frequently mentioned reason 
why women felt they were not at risk of 
getting HIV (39.7 percent). Using condoms 
every time they had sex (20.2 percent) and 
getting tested regularly (13.6 percent) were 
the next most frequently mentioned reasons 







18-19 20-24 25-29 30-34 35-39 40-44 45-49 50-70
Ever tested for HIV
Tested in the last
year
Tested more than




Table 4 shows the key reasons (and 
their frequency) why women 
considered themselves to be at risk 
of getting HIV. Not knowing a 
partner’s HIV status was the most 
frequently mentioned reason (23.8 
percent), followed by worry that 
their partner has other partners 
(19.7 percent) and not having used 
a condom at last vaginal sex (16.6 
percent).  
Association between 
composite measure of risk 
and self-assessed risk 
A composite measure of risk (CMR) 
of HIV was calculated based on the 
number of affirmative responses to 
eight questions on the self-
administered anonymous 
questionnaire (see Table 5).  The 
CMR was calculated for all women 
who reported they were HIV 
negative (n=766) on the 
anonymous questionnaire, with the 
exception of those who didn’t 
respond to question about self-assessed risk (n=71), making a total of 695 women in the CMR calculation.   
 
The CMR was divided into categories 
of risk, based on the number of 
affirmative responses to the 8 
questions, are as follows:  no risk (0); 
low risk (1); medium risk (2), high risk 
(3-6); no women responded 
affirmatively to more than six 
questions.   
Chi-square was then used to measure 
the association between the CMR and 
self-assessed risk. Among women who 
self-assessed as having no risk of HIV, 
30 percent had a CMR of 0, meaning 
they answered “no” to all questions. 
Eleven percent of the women who self-
assessed as having no risk of HIV had a CMR of 3 or higher, compared to 23 percent of the women who self-
assessed as being at high risk of HIV. The associations between the CMR score and women’s self-assessed level of 
risk was tested with a chi-square test and was highly significant (p=0.0044).  
As shown in Table 6, participants in the green highlighted cells (20.3 percent) had a self-assessment similar to their 
CMR, participants in the orange highlighted cells (26.5 percent) may be overestimating their risk, and participants in 
the blue highlighted cells (23.6 percent) may be underestimating their HIV risk. Additionally, 29.6 percent of 
participants did not know their risk. 
  
TABLE 4  Reasons women think they are at risk of getting HIV 
Why do you think you are at risk of getting HIV?*  N = 605 Percent 
I had sex with more than one partner in the past 3 months   55   9.0 
I do not know my partner’s HIV status 146 23.8 
I did not use a condom last time I had vaginal sex 102 16.6 
I did not use a condom last time I had anal sex   48   7.8 
I am worried that my partner has other partners 121 19.7 
I am worried that my partner uses drugs     8   1.3 
I am using drugs     3   0.5 
I am in a polygamous marriage     5   0.8 
I am a sex worker     3   0.5 
Sometimes my partner is violent/abusive to me     9   1.5 
I sometimes have sex in exchange for goods or money     7   1.1 
Other reason for risk of HIV   10   1.6 
I don’t know 125 20.4 
Refuse to answer   48   7.8 
*Denominator includes women who responded to any of the subsequent reasons for being at 
risk. 
** N’s do not add up to 100% because multiple responses were possible.  
 
TABLE 5  Questions included in the CMR (N = 695) 
 
N Percent 
Don’t know own HIV status 99 12.9 
Don’t know husband or primary partner’s HIV status 349 45.6 
Husband or primary partner is HIV-positive    16   4.5 
Ever had an STI 129 16.8 
Never used a condom during vaginal sex 135 17.6 
Had anal sex in past 3 months 112 14.6 
Partner forced sex in last 12 months   56   7.3 





TABLE 6  Self-assessed Risk, by CMR (n=695) 
Composite  
measure of risk 
No risk Low risk Medium risk High risk Don't know Total 
0   43 (6.18%)   39 (5.61%) 13 (1.87%)   26 (3.74%)   43 (6.19%) 164 
1   55 (7.9%)   48 (6.91%) 32 (4.6%)   35 (5.04%)   78 (11.22%) 248 
2   29 (4.17%)   29 (4.17%) 20 (2.88%)   39 (5.61%)   53 (7.63%) 170 
3-6   15 (2.16%)   21 (3.02%) 15 (2.16%)   30 (4.32%)   32 (4.6%) 113 
Total 142 137 80 130 206 695 
Note: 71 women did not respond to the self-assessed risk question and are excluded from the table. 
Green=Self-assessment similar to their CMR; Orange=May be overestimating their risk; Blue=May be underestimating their HIV risk. 
 
Although there are limitations to the interpretation of this information in the absence of a biomarker that would 
provide a more accurate measure of HIV risk, these data contribute important information as to how women assess 
their level of risk. Women both under- and overestimate their level of risk as calculated by the CMR. Slightly more 
than half of all women either did not know their risk (29.6 percent) or underestimated their risk (23.6 percent) as 
per the CMR. Perhaps most worrisome is the women who appear to underestimate their risk, as it is unlikely that a 
woman who perceives herself to be at low or no risk would be motivated to adopt prevention practices or willing to 
use an ARV-based prevention product. Only about 20 percent of women seem to have a relatively accurate self-
assessment of their risk as measured by the CMR. 
OBJECTIVE 2  
Document clients’ perspectives on ARV-based prevention and tenofovir gel specifically, including their interest and 
willingness to try such products in the future. 
Very few women said they had ever heard of PrEP (3 percent), vaginal microbicides in general (7 percent), and 
tenofovir gel specifically (8 percent). After being provided with a brief description of tenofovir gel, 94 percent said 
they would be willing to try it on its own (56 percent) or in combination with another method (39 percent). Other than 
more generally being interested in a prevention method, the most commonly reported reasons for wanting to try 
tenofovir gel were not trusting partners (12 percent) or disliking condoms (8 percent). When asked about potential 
concerns using the gel, 21 percent said they would worry that it might cause side effects; in general, 3 percent were 
worried specifically about potential side effects for their partners and 3 percent were concerned about harm if one 
were to get pregnant while using the gel. The majority of women (more than 95 percent) had no concerns about the 
gel reducing sexual pleasure (for themselves or their partners), although 7 percent said they were concerned it 
might cause too much wetness.  
Most women (92 percent) said they would prefer to get the product from a clinic, preferably from a nurse (80 
percent), versus a pharmacy or other outlet, and 68 percent said they would only use it if it were free. The majority 
(82 percent) thought that a vaginal gel used only around the time of sex would be easier to use than a daily oral pill. 
When asked how frequently they would be willing to come to a clinic (or elsewhere) for resupply, 53 percent said 
monthly and 22 percent said every three months. Similarly, half of the women said they would be willing to be tested 
for HIV every three months if it was a prerequisite for product resupply, and an additional 22 percent said they would 
be willing to get tested once a month.  
OBJECTIVE 3  
Gather insights from a select number of facility and program managers about the potential role that tenofovir gel 
could play in their programs and the challenges and opportunities of introducing the product. 
Semistructured interviews were conducted with facility managers from each of the three districts in Mpumalanga 
where the study was conducted, and one district manager from Maternal, Child and Women’s Health. They shared 




treatment, and care. They were then asked about challenges and opportunities for tenofovir gel introduction. Key 
insights and themes emerging from the interviews are highlighted. 
 
Service delivery 
Respondents were asked to provide a general description of the services at PHC facilities. While it is not possible to 
verify the degree to which these services are operational in all centers, below is an overview of the possible 
constellation of services offered at these facilities.  
HIV prevention services:  
• provider initiated counseling and testing (PICT) 
• voluntary HIV counseling and testing (HCT) 
• post-exposure prophylaxis (PEP) 
• prevention of mother-to-child transmission (PMTCT) 
• provision of male and female condoms 
• prevention and treatment of STIs 
• cervical cancer screening 
• in some settings, medical male circumcision 
Services for HIV-positive patients:  
• prevention and management of TB 
• provision of ARVs 
• adherence counseling 
• monitoring of CD4 count 
• support groups 
The overall goal is for all clients attending PHC centers—regardless of reason—to be offered HIV counseling and 
testing. In principle, HIV prevention is integrated with other services so that all clients are encouraged to be tested; 
the degree to which this happens in practice is less clear.  
While one might expect service-delivery practices to be standardized across PHC clinics, there is variation in how 
they are rolled out. For example, in the case of PEP, most clinics do not actually offer it. At clinics where PEP is 
provided for accidental exposure, it is not actively offered; rather it is available for those who are aware of it and 
seek it out. Even in the case of rape, procedures vary between clinics within the same province. For example, while 
most clinics provide PEP for rape, some refer women to the police station first to file a report and then refer them to 
the hospital for PEP and other services. In other cases, the clinic provides PEP to HIV-negative women immediately 
and then refers them to the hospital for forensic management of rape.  
This example highlights the variability in service delivery even within the context of PHC clinics. 
HIV testing and retesting practices 
Pregnant women, young people, and women seeking FP reportedly seek out HCT most frequently. Testing practices 
within ANC services differ among clinics, even within the same province. At one clinic, for example, a new policy was 
implemented wherein pregnant women were to be tested every six weeks (versus only at first prenatal visit and at 
32 weeks). Importantly, even the protocol of testing at 32 weeks was not being consistently implemented. It was not 
clear whether this was because nurses were not offering the testing or women did not want it.  
The general recommendation for PHC clinics is to try to get everyone tested at least once a year. When clients test 
negative, they are encouraged to return for repeat testing three months later to confirm the negative result. It has 




test positive are referred to a variety of services including wellness clinics, adherence counseling, psychosocial 
support, treatment of opportunistic infections, monitoring of CD4 count and viral load, and, as soon as eligible, 
initiation of ARV therapy. In some instances, home-based care teams follow up with HIV-positive clients who do not 
return to the clinic for treatment or monitoring. 
Workforce, record-keeping, logistics  
When asked about the challenges to providing high-quality services, most respondents described a lack of human, 
physical, and financial resources, with an emphasis on the burden on nurses. There are few medical doctors on 
staff; nurses perform the majority of all services. A few respondents indicated that clients would prefer to receive 
HCT from a nurse who they are seeing for another service, rather than from a lay counselor who specifically provides 
HCT, both for confidentiality reasons and convenience. 
Shortage of space, heavy client load, and difficulty in providing continuity of care for clients were also seen as 
challenges. Several respondents described limited space—often only one private room in a clinic—for HCT. Stock-
outs of supplies, including HIV test kits, was noted as a problem but one that could be alleviated with better 
forecasting. There was an overall sense of frustration on the part of clinic staff regarding record-keeping. Although 
registers are used, the information that is captured is not comprehensive, not always accurate, and is variable from 
one site to another. Only one clinic has an electronic system (Tier 2) that captures information on all clients coming 
for HCT and their HIV test results 
Despite these challenges, respondents indicated that in general clients are pleased with the quality of actual 
services received but are frustrated by long wait times, and distance and travel time to the clinic.  
Program managers’ attitudes toward tenofovir gel/microbicides 
Given that most of the respondents had little knowledge of microbicides or tenofovir gel, the study team provided 
standard information and basic facts about microbicides, and tenofovir gel specifically. Despite the inherent 
challenges of asking about attitudes and opinions concerning products that are not yet available, useful information 
was gleaned from this select group of program managers. Specifically, program managers were asked about 
whether this was a product they could envision providing, and if so, where and to whom.  
•  Most thought it would be best to offer such a product within the context of routine services, the way HCT is 
offered to anyone coming to PHC facilities, including within FP clinics. There was a clear recognition that married 
women and those coming for FP are in need of protection.  
• Opinions ranged as to whether tenofovir gel would be most beneficial for young people, married women, sex 
workers, or any woman who considers herself at risk.  
When asked about the concerns they might have in offering tenofovir gel, several issues emerged. For example, 
some expressed concern about: 
• The regimen itself (e.g., the understanding that the gel would have to be applied 12 hours prior to sex), 
maintaining adequate supplies, and how clients would store the product at home.  
• The potential of users abandoning the condom for gel (condom migration); 
• The type, severity, and likelihood of side-effects; and whether HIV drug resistance was a concern.  
Respondents felt they needed more information about:  
• The safety of the gel; when it could and should be applied. 
• Whether there was an age limit (e.g., whether older women could use it). 
• Whether it could be used by women who are pregnant, menstruating, or who had an active STI. 
• How often it could be used, for what length of time, and whether it could protect over multiple sex acts. 
None of the respondents were aware of the intravaginal rings (IVRs) being tested for HIV prevention. When asked if 
they thought the gel or an IVR would be preferable, most thought a gel would be preferred, if only because it was 









IMPLICATIONS FOR INTRODUCTION OF 
ARV-BASED PREVENTION PRODUCTS 
FOR WOMEN 
Although this study was focused on the potential introduction of tenofovir gel, the lessons and insights are relevant 
to the introduction and planning of any ARV-based prevention product for women. While intentionality does not 
necessarily translate into actual use, the fact that the vast majority of women said that they would be “willing to try” 
tenofovir gel, despite having never heard of it prior to the study, suggests some level of interest.  
Regardless of the future of tenofovir gel, this study provides valuable information regarding women’s assessment of 
their individual HIV risk, testing practices, and service- delivery patterns. Given that most women came to the clinics 
for FP, ANC, or HCT, identifying effective ways to integrate any new ARV-based prevention product into these types of 
services would be useful. Further, women who attended FP and/or well-baby services tended to have been tested 
more often than those seeking other services. This suggests that repeat testing is possible, particularly if done within 
the context of these services. The data on HIV-testing patterns is important as it indicates that many women are 
already being tested regularly for HIV—a prerequisite for provision of any ARV-based prevention product. Finally, 
program managers provided important suggestions for readying health systems for a new ARV-based prevention 
product, including establishing awareness-raising campaigns, training providers (particularly nurses), and educating 
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Boulders Marite Allamansdrift B Piet Retief Fernie 1 
      
Setting Rural  Rural Rural Urban Rural 
Hours M–F; 8am–4pm  7 days/week; 7am–4pm  M–F; 7am–4pm M–F; 7am–4pm 7 days/week; 7am–7pm 
Staffing  • 5 Professional nurses 
(PNs) 
• 2 Enrolled nurses 
(ENs) 
• 2 Lay counselors 
• 1 General assistant 
• 1 Gardener 
• 1 Medical doctor 
(MD) (comes once 
per week) 
• 6 PNs 
• 3 ENs 
• 1 Nursing assistant 
(NA) 
• 1 Data capturer 
• 3 Lay counselors  
• 1 General assistant 
• 3 PNs 
• 1 EN 
• 1 NA 
• 1 Data capturer 
• 1 Lay counselor 
• 1 General assistant 
• 1 Gardener 
• 12 Home-based care-
givers 
• 11 PNs  
• 3 Staff nurses 
• 3 Lay counselors 
• 1 Data capturer 
• 1 GA 
• 1 Groundsman  
• 2 Volunteers 
• Outreach team (1 PN, 2 
CHW) 
• 4 PNs 
• 1 EN 
• 3 NAs 
• 2 Administrative clerks 
• 2 Clerks  
• 2 GAs 
• 3 Lay counselors 
Services • ANC 
• Chronic diseases 
• Delivery 






• Chronic diseases 
• Delivery 




• Well-baby  
• Wellness  
• ANC 
• Cancer screening 
• Chronic disease 
• Emergency deliveries 
only 
• Family planning  
• Minor ailments 
• PNC  
• SRH (Pregnancy 
testing, TOP 
counseling, referrals) 
• STI  
• TB  
• ANC 
• Cancer screening  
• Chronic disease 
• EPI, child health, 
nutrition; food parcels as 
needed 
• Family planning  
• Minor ailments 
• PNC  
• STI  
• TB  
• ANC and PMTCT 
• Chronic diseases 
• Delivery 
• Family planning 










• Injectables  
• Oral contraceptives 
(OCs) 
• Male and female 
condoms  
• Injectables  
• OCs 
• Male and female 
condoms  
• Injectables  
• OCs 
• Male and female 
condoms 
• Implant and IUDs— 
introduced but 
stopped a few months 
later 
• Injectables  
• OCs 
• Male and female 
condoms 
• Injectables  
• OCs 
• Male and female 
condoms  
• Implant and IUDs— 
introduced but 








• HCT and Rx PrEP 
provided by 2 lay 
counselors. 
• Rx provided by MD 
and PNs. 
• Lay counselors do 
follow-up and 
adherence assess-
ments.   
• PEP provided for 
sexual assault or 
rape; survivors 
assessed and 
referred to hospital.  
• HCT and treatment 
PrEP provided by 3 lay 
counselors. 
• After clients start 
ARVs, seen by 
providers attending to 
all chronic care.  
• PEP provided for 
sexual assault or rape; 
survivors assessed 
and referred to 
hospital for PEP. 
• PEP provided for burst 
condom; offered by 
PNs. 
• HTC. 
• HIV care and support. 
• ARV provision. 
• PEP offered for rape, 
sexual assault, and 
burst condoms. 
• HTC. 
• HIV care and support. 
• ARV provision. 
• PEP offered for rape, 
sexual assault, and burst 
condoms. 
• Services provided in 2 
consulting rooms by 
counselors and 1 nurse. 
• HTC. 
• ARV treatment. 
• HIV care and support. 
• PEP for sexual assault 
or rape; survivors 
referred to MD who 
provides PEP. 
• PEP for burst condom 
is offered by PNs. 
• MCC is done 1 
day/week by MD from 
nearby provisional 
hospital.  
• Services are provided 
by the counselors, who 
work in shifts and are 
available at the clinic 
throughout the day. 
There are 2 rooms 




• 30 people/day 
• Mostly adults; mainly 
female. 
• 4,000 clients/month. 
• Mostly adults; more 
females.  
• Busy all day. 
• 3 buildings: 1 for 
chronic treatments 
(incl. HIV and TB), 
minor ailments, SRH; 1 
for well-baby, ANC; 1 
for HCT.  
• Works with local CBOs 
for outreach. 
• 1,300 clients/month 
• Mostly adults, but 
more females 
• All services every day 
of the week 
• Small clinic; limited 
space. 
• Very busy in the morning. 
• Long wait times.  
• Approximately 100 
clients/day. 
• More females and 
older clients than 
males and young 
people. 
PN = Professional nurse; EN = Enrolled nurse; GA = General assistant; MD = Medical doctor; NA = Nursing assistant; CHW = Community health worker;  
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